Galectin-3 predicts response and outcomes after cardiac resynchronization therapy.https://www.ncbi.nlm.nih.gov/pubmed/30390680

In the Emergency Department, accurate diagnosis in a minimum of time is critical to ensure the best patient outcomes.https://www.biomerieux-diagnostics.com/emergency-department-patient-management https://www2.cscc.unc.edu/aric/node/9824 https://onlinelibrary.wiley.com/doi/full/10.1002/rth2.12038

https://www.accessdata.fda.gov/cdrh_docs/pdf14/K140436.pdf

70th AACC Annual Scientific Meeting Abstracts, 2018. Race- and Sex- Dependent Association of BNP and Galectin-3 Levels
with 6-Month All-Cause Mortality in Patients with Elevated BNP.
file:///C:/Users/asus/Downloads/A65A113%20(4).pdf

The Predictive Value of Plasma Brain Natriuretic
Peptide and Galectin-3 in Elderly Patients Admitted
for Heart Failure file:///C:/Users/asus/Downloads/diseases-06-00088.pdf
https://www.ncbi.nlm.nih.gov/pubmed/30262779

Galectin-3 Reflects the Echocardiographic Grades of Left Ventricular Diastolic Dysfunction.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5895859/

https://www.barrons.com/articles/BL-TB-19106

https://www.otcmarkets.com/stock/BGMD/security

OTC Markets 08/27/2018 Transfer Agent Verified

https://patents.justia.com/patent/20150080463
https://www.bmj.com/content/357/bmj.j1648

New old test?-PCSK9,Mirnext,miRNAs,http://www.ctmm.nl/en/downloads/projects-downloads/triumph-output-report

It is interesting: 1. Methods for predicting cardiovascular events and monitoring treatment using pcsk9 (Patent).
2. …measured plasma PCSK9 levels in a subset of participants with a sandwich enzyme linked immunosorbent assay using antibodies supplied by …
Low LDL cholesterol, PCSK9 and HMGCR genetic variation, and risk of Alzheimer’s disease and Parkinson’s disease: Mendelian randomisation study (June 29, 2017)

It is interesting: DEF-14A 06/23/2016… Board of Directors currently consists of five members, classified into three classes as follows: Jeffrey R. Luber and Stelios Papadopoulos, Ph.D. constitute a class I with a term ending at our annual meeting of stockholders to be held in 2018; James F. O’Connor constitutes a class II with a term ending at our 2016 annual meeting of stockholders; and Harry W. Wilcox and Paul R. Sohmer, M.D. constitute a class III with a term ending at our annual meeting of stockholders to be held in 2017. On March 25, 2016, our Board of Directors accepted the recommendation of the Nominating and Governance Committee and voted to nominate James F. O’Connor for election at the annual meeting for a term of three years to serve until the 2019 annual meeting of stockholders…Manipulation: 200 sell (-42%) ?2018 annual meeting of stockholders...?

Galectin-3: A new post-MI prognostic biomarker?https://www.mdedge.com/ecardiologynews/article/168394/acute-coronary-syndromes/galectin-3-new-post-mi-prognostic-biomarker

Galectin-3: One Molecule for an Alphabet of Diseases, from A to Z.
http://www.mdpi.com/1422-0067/19/2/379/htm

Today CARV +200%,when BGMD FLY???

I want to buy shares.Anybody now why STOP t.?

Galectin-3 test in development-Alinity assay menu (Abbott).cardioSCORE? https://www.corelaboratory.abbott/sal/launchMaterial/ADD-00059733_Alinity%20ci%20International%20Assay%20Menu.pdf

The 2016 annual meeting of stockholders (August 5, 2016). 2017?

Any news from shareholders meeting?

Galectin-3 test under development in ADVIA Centaur XP Immunoassay System (Siemens) –test BGMD???
https://www.healthcare.siemens.nl/immunoassay/systems/advia-centaur-xp/assays

BG Medicine and Siemens Healthcare Diagnostics (Galectin-3 test)?

Galectin-3 test-Architect i 2000srAbbott and VIDAS® bioMerieux.
BGMD Mkt cup 420 000$?

http://onlinelibrary.wiley.com/doi/10.1002/rth2.12038/full